As PSMA is overexpressed in prostate cancer cells compared to benign tissue, the therapeutical radiation dose is accumulated at the tumour site, limiting radiation damage to non-PSMA-expressing tissues and reducing damage to healthy tissues. Here, FOLH1 is linked to prostate cancer.